Innovative Therapeutic
Devices Addressing
Significant Unmet Needs
Latest News
Fibralign wins Medtech Innovator Award
Fibralign won the prestigious Medtech Innovator award at the 2014 WSGRC Medical Device Conference, placing first out of over 300 startups for this top honor and $125,000 prize.
Fibralign set to bring new device option for secondary lymphedema
A young company developing a product to address secondary lymphedema, a chronic disease with no cure, stole the show at a venture competition held during a recent medical device conference. Working with Stanford University (Stanford, California), Fibralign (Sunnyvale,...
About Us
Fibralign is an award-winning, Stanford-spinout company that produces novel therapeutic biomedical devices that are designed to address major unmet medical needs.
The company has launched its first product, the BioBridge Collagen Matrix, which has received FDA 510(k) clearance for use in soft tissue repair. The company is currently studying BioBridge for use in treating secondary lymphedema, a global chronic disease that currently has no cure
BioBridge® Collagen Matrix
- FDA 510(k) cleared device for use in soft tissue repair.
- BioBridge currently being studied for use in treating secondary lymphedema.
- FDA 510(k) cleared device*
- CE mark approved, Class III device
- Commercially available now in the US and Europe
* BioBridge has not been approved by the FDA for treating secondary lymphedema.
Nanoweave® Technology
Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means to precisely print 3D scaffolding in such a way that mimics human tissue nano structure and directly influence the body’s repair function.
Grants, Awards, Partners and Collaborators
Fibralign has been recognized for its vision and potential to impact lives globally. We are supported in our mission by world class partners and collaborators.